Form 8-K Viridian Therapeutics, For: Sep 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Viridian Therapeutic (VRDN) PT Raised to $44 at RBC Capital
September 13, 2024 6:33 AM EDTRBC Capital analyst Gregory Renza raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $44.00 (from $35.00) while maintaining a Outperform rating.
The analyst comments "This week's pivotal ph.III THRIVE topline for veligrotug (Veli'; VRDN-001 IV) in active TED came in as a... More
